[go: up one dir, main page]

ATE261126T1 - Verfahren für lösung-basierte diagnose - Google Patents

Verfahren für lösung-basierte diagnose

Info

Publication number
ATE261126T1
ATE261126T1 AT02017313T AT02017313T ATE261126T1 AT E261126 T1 ATE261126 T1 AT E261126T1 AT 02017313 T AT02017313 T AT 02017313T AT 02017313 T AT02017313 T AT 02017313T AT E261126 T1 ATE261126 T1 AT E261126T1
Authority
AT
Austria
Prior art keywords
diagnosis
solution
medically relevant
markers
substitute
Prior art date
Application number
AT02017313T
Other languages
English (en)
Inventor
Ruediger Ridder
Wolfgang Rudy
Matthias Herkert
Marcus Trunk-Gehmacher
Anja Reichert
Knebel Doeberitz Magnus Von
Original Assignee
Mtm Lab Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mtm Lab Ag filed Critical Mtm Lab Ag
Application granted granted Critical
Publication of ATE261126T1 publication Critical patent/ATE261126T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57411—Specifically defined cancers of cervix
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5076—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving cell organelles, e.g. Golgi complex, endoplasmic reticulum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • External Artificial Organs (AREA)
AT02017313T 2002-08-01 2002-08-01 Verfahren für lösung-basierte diagnose ATE261126T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02017313A EP1388734B1 (de) 2002-08-01 2002-08-01 Verfahren für Lösung-basierte Diagnose

Publications (1)

Publication Number Publication Date
ATE261126T1 true ATE261126T1 (de) 2004-03-15

Family

ID=30129176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02017313T ATE261126T1 (de) 2002-08-01 2002-08-01 Verfahren für lösung-basierte diagnose

Country Status (13)

Country Link
US (3) US7517662B2 (de)
EP (2) EP1388734B1 (de)
JP (4) JP2005534313A (de)
CN (1) CN100570366C (de)
AT (1) ATE261126T1 (de)
AU (1) AU2003262554B2 (de)
CA (1) CA2487048C (de)
DE (1) DE60200248T2 (de)
DK (1) DK1388734T3 (de)
ES (1) ES2215957T3 (de)
MX (1) MXPA04012648A (de)
RU (1) RU2315312C2 (de)
WO (1) WO2004013632A1 (de)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
WO2002101075A2 (en) * 2001-06-13 2002-12-19 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US8986944B2 (en) 2001-10-11 2015-03-24 Aviva Biosciences Corporation Methods and compositions for separating rare cells from fluid samples
US8980568B2 (en) 2001-10-11 2015-03-17 Aviva Biosciences Corporation Methods and compositions for detecting non-hematopoietic cells from a blood sample
EP1369694A1 (de) 2002-04-09 2003-12-10 MTM Laboratories AG Verfahren zur Unterscheidung zwischen Metaplasien und neoplastischen oder präneoplastischen Läsionen
US7402397B2 (en) 2002-05-21 2008-07-22 Monogram Biosciences, Inc. Detecting and profiling molecular complexes
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
EP1422526A1 (de) 2002-10-28 2004-05-26 MTM Laboratories AG Verfahren zur verbesserten Diagnose von Dysplasien
ATE289685T1 (de) 2003-08-25 2005-03-15 Mtm Lab Ag Verfahren zum nachweis von karzinomen in solubilisierten zervikalen körperproben
EP1510820B1 (de) * 2003-08-25 2010-03-17 MTM Laboratories AG Verfahren zum Nachweis von medizinisch relevanten Zuständen in gelösten LBC-Proben
EP1681983A4 (de) * 2003-10-14 2008-12-10 Monogram Biosciences Inc Rezeptor-tyrosin-kinase-signalpfad-analyse für diagnose und therapie
CA2557438C (en) 2004-02-19 2017-01-17 Yale University Identification of cancer protein biomarkers using proteomic techniques
DE102004009934A1 (de) * 2004-02-26 2005-09-22 Niendorf, Axel, Prof.Dr.med. Verfahren zur Untersuchung einer Gewebeprobe
US7229778B2 (en) 2004-02-26 2007-06-12 The Procter & Gamble Company Methods for determining the relative benefits and/or evaluating quantitative changes of products on epithelial tissue
ES2381644T3 (es) * 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
EP1767647B1 (de) * 2004-05-31 2010-11-24 Sysmex Corporation Verfahren zur beurteilung der malignität einer säuger-krebszelle
GB0413001D0 (en) 2004-06-10 2004-07-14 Johnson & Johnson Medical Ltd Diagnostic and prognostic
EP1628135A1 (de) * 2004-08-20 2006-02-22 MTM Laboratories AG Verfahren zum Nachweis von medizinisch relevanten Zuständen in gelösten LBC Proben
ITBO20040576A1 (it) * 2004-09-17 2004-12-17 Alma Mater Studiorum Uni Di Bologna Metodo e kit per la valutazione della frammentazione di dna a seguito di esposizione a radiazione
WO2006043938A1 (en) * 2004-10-14 2006-04-27 Genentech, Inc. Cop1 molecules and uses thereof
ATE519109T1 (de) * 2004-12-21 2011-08-15 Univ Yale Präeklampsie-diagnose
US7595380B2 (en) 2005-04-27 2009-09-29 Tripath Imaging, Inc. Monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007013949A2 (en) * 2005-07-21 2007-02-01 Wayne State University Asbestos exposure, pleural mesothelioma, and serum osteopontin levels
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US7632498B2 (en) 2005-12-19 2009-12-15 Tripath Imaging, Inc. MCM6 and MCM7 monoclonal antibodies and methods for their use in the detection of cervical disease
WO2007085043A1 (en) * 2006-01-24 2007-08-02 Mycrolab Pty Ltd Methods for low cost manufacturing of complex layered materials and devices
ATE437355T1 (de) * 2006-02-03 2009-08-15 Mtm Lab Ag Verfahren zur durchführung eines denaturierungs- immunoassays
WO2007103770A2 (en) * 2006-03-02 2007-09-13 Ppd Biomarker Discovery Sciences, Llc Compositions and methods for analyzing renal cancer
US8768629B2 (en) * 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
WO2007137187A2 (en) 2006-05-18 2007-11-29 Molecular Profiling Institute, Inc. System and method for determining individualized medical intervention for a disease state
US20100113299A1 (en) * 2008-10-14 2010-05-06 Von Hoff Daniel D Gene and gene expressed protein targets depicting biomarker patterns and signature sets by tumor type
CN101583722A (zh) 2006-07-14 2009-11-18 阿维瓦生物科学股份有限公司 从生物学样品检测稀有细胞的方法和组合物
CN105699662A (zh) * 2006-11-02 2016-06-22 协和梅迪克斯株式会社 免疫测定待测组分的方法
US8968995B2 (en) 2008-11-12 2015-03-03 Oncohealth Corp. Detection, screening, and diagnosis of HPV-associated cancers
US8865162B2 (en) 2008-06-13 2014-10-21 Oncohealth Corp. Monoclonal antibodies against HPV proteins
US8877507B2 (en) * 2007-04-06 2014-11-04 Qiagen Gaithersburg, Inc. Ensuring sample adequacy using turbidity light scattering techniques
CA3117744C (en) * 2008-09-04 2022-07-19 Ventana Medical Systems, Inc. Method for prediction of the progression risk of tumors
GB2463401B (en) * 2008-11-12 2014-01-29 Caris Life Sciences Luxembourg Holdings S A R L Characterizing prostate disorders by analysis of microvesicles
EP2224244A1 (de) * 2009-02-26 2010-09-01 Universität des Saarlandes In-vitro-Diagnoseverfahren oder Assay zur Diagnose der chronischen obstruktiven Lungenerkrankung
JP2012526286A (ja) * 2009-05-07 2012-10-25 オンコヘルス コーポレーション ヒトパピローマウイルス（ｈｐｖ）およびｈｐｖ関連癌の初期段階および後期段階の検出、スクリーニング、および診断のための高度または≧ｃｉｎ２の同定
EP2270510A1 (de) * 2009-07-02 2011-01-05 EMBL (European Molecular Biology Laboratory) Diagnoseverfahren zur Vorhersage des Krebsrekurrenzrisikos basierend auf Histon-macroH2A-Isoformen
CN101942017B (zh) * 2009-07-07 2013-08-14 清华大学 一种新的肿瘤标志物
EP2333105A1 (de) * 2009-12-08 2011-06-15 Koninklijke Philips Electronics N.V. Selektive Lyse von Zellen
EP2521914A4 (de) 2010-01-08 2013-07-10 Oncohealth Corp Zellbasierte hpv-immuntests mit hoher durchlaufleistung zur diagnose und abtastung von hpv-assoziierten krebsen
WO2011103274A1 (en) 2010-02-17 2011-08-25 Gen-Probe Incorporated Compositions and methods to detect atopobium vaginae nucleic acid
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US20130165334A1 (en) * 2010-03-04 2013-06-27 Andrew A. Bieberich Integrated assay that combines flow-cytometry and multiplexed hpv genotype identification
EP2556172A4 (de) 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings Zirkulierende biomarker für krankheiten
RU2464570C2 (ru) * 2010-11-19 2012-10-20 Федеральное государственное учреждение "Российский научный центр рентгенрадиологии" Министерства здравоохранения и социального развития России Метод диагностики цервикальных интраэпителиальных неоплазий
EP2702166B1 (de) 2011-04-25 2018-06-06 Gen-Probe Incorporated Zusammensetzungen und verfahren zum nachweis von bv-assoziierter bakterieller nukleinsäure
CN107012078B (zh) * 2011-05-05 2020-11-06 安派科生物医学科技有限公司 肿瘤细胞检测仪
US8859215B2 (en) 2011-06-30 2014-10-14 Ge Healthcare Bio-Sciences Ab Cell binding assay
WO2013016449A2 (en) * 2011-07-26 2013-01-31 Indicator Systems International, Inc. Assays for the detection of microbes
WO2013036928A1 (en) 2011-09-08 2013-03-14 Gen-Probe Incorporated Compositions and methods for detecting bv-associated bacterial nucleic acid
ES2847867T3 (es) * 2011-11-03 2021-08-04 Tripath Imaging Inc Métodos y composiciones para preparar muestras para inmunotinción
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
RU2508542C1 (ru) * 2012-07-16 2014-02-27 Полина Михайловна Шварцбурд Экспресс-способ определения риска злокачественности клеток
EP2895623B1 (de) 2012-09-17 2018-08-22 Agios Pharmaceuticals, Inc. Verwendung von e-cadherin und vimentin zur auswahl von auf eine behandlung ansprechenden patienten
AU2013205122B2 (en) 2012-10-11 2016-11-10 Gen-Probe Incorporated Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid
EP2922832B1 (de) 2012-11-21 2019-10-09 Agios Pharmaceuticals, Inc. Glutaminasehemmer und verfahren zur verwendung
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US9029531B2 (en) 2012-11-22 2015-05-12 Agios Pharmaceuticals, Inc. Compounds and their methods of use
RU2538618C2 (ru) * 2012-12-26 2015-01-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Петрозаводский государственный университет" Способ дифференциальной диагностики цервикальных дисплазий и рака шейки матки
SG11201507333XA (en) * 2013-03-15 2015-10-29 Genentech Inc Biomarkers and methods of treating pd-1 and pd-l1 related conditions
RU2535042C1 (ru) * 2013-11-25 2014-12-10 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздрава России) Способ определения биологического возраста трупа при длительной кровопотере
CA2943339A1 (en) 2014-03-21 2015-09-24 Agios Pharmaceuticals, Inc. Compounds and their methods of use
MX2017000419A (es) 2014-07-11 2017-08-16 Genentech Inc Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
KR101858801B1 (ko) * 2015-01-30 2018-05-17 중앙대학교 산학협력단 혈중 항체의 당질분석을 통한 자궁경부암의 진단방법 및 이를 이용한 진단키트
EP4060344A1 (de) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Verfahren und kits
CN107771285A (zh) 2015-06-08 2018-03-06 阿奎尔诊断有限公司 方法
CN108267586A (zh) * 2016-12-30 2018-07-10 苏州和锐生物科技有限公司 一种人ck18蛋白检测试剂及其制备方法
JP7194128B2 (ja) * 2017-06-29 2022-12-21 イェンタイ クワンティシジョン ディアグノスティックス インク 固形腫瘍の診断用のバイオマーカーの絶対定量の方法および装置
AU2019351824A1 (en) 2018-10-01 2021-05-27 Gen-Probe Incorporated Compositions and methods for amplifying or detecting varicella-zoster virus
CN111257565A (zh) * 2018-12-03 2020-06-09 上海细胞治疗集团有限公司 一种衰老细胞的检测试剂盒及其检测方法
CN109781977B (zh) * 2019-01-09 2022-03-29 首都医科大学附属北京安定医院 IL15Rα以及相关膜蛋白检测试剂盒及其应用
CN110672558B (zh) * 2019-09-24 2022-05-10 东南大学 基于oct技术的神经活动观测方法及系统
CN113702341B (zh) * 2020-05-22 2022-08-16 中国科学院大连化学物理研究所 一种过氧化物酶催化的细胞表面蛋白质标记方法
JPWO2022264545A1 (de) * 2021-06-17 2022-12-22
CN113985028A (zh) * 2021-11-25 2022-01-28 济南百博生物技术股份有限公司 一种用于胶体金法抗原检测稀释液
CN115389598A (zh) * 2022-09-27 2022-11-25 达碧清诊断技术(上海)有限公司 糖化血红蛋白的快速聚焦电泳定量分析方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US86288A (en) * 1869-01-26 Improvement in bbeb-drill and corn-covereh
US39023A (en) * 1863-06-23 Improvement in churns
US4281061A (en) * 1979-07-27 1981-07-28 Syva Company Double antibody for enhanced sensitivity in immunoassay
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE3923951A1 (de) 1989-07-19 1991-01-31 Boehringer Mannheim Gmbh Verfahren zum nachweis von leberzirrhose
JPH0580053A (ja) * 1991-03-22 1993-03-30 Shiro Nozawa ヒト子宮体癌細胞の免疫化学的検出方法
US5776783A (en) * 1993-11-02 1998-07-07 Private Clinic Laboratories, Inc. Method of monitoring therapeutic agent consumption
US6316208B1 (en) * 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
CA2164167A1 (en) * 1994-12-20 1996-06-21 Izak Bahar Assay normalization method
US6033847A (en) * 1995-02-06 2000-03-07 St. Jude Children's Research Hospital InK4c-p18 and InK4d-p19, inhibitors of cyclin-dependent kinases CDK4 and CDK6, and uses thereof
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5976799A (en) * 1996-03-21 1999-11-02 The Board Of Trustees Of The University Of Arkansas Early detection of ovarian carcinoma using P16 gene products
GB9616429D0 (en) 1996-08-05 1996-09-25 Quantum Biosystems Ltd Assessment of cervical cells
US5858683A (en) * 1996-08-30 1999-01-12 Matritech, Inc. Methods and compositions for the detection of cervical cancer
JP4427106B2 (ja) * 1997-03-18 2010-03-03 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 平滑筋腫を治療および診断するための方法およびキット
AU8403098A (en) * 1997-07-15 1999-02-10 Deaconess Hospital Reagents and methods for diagnosis and prognosis of proliferative disor ders
WO1999044067A1 (en) 1998-02-25 1999-09-02 New York Medical College FLOW CYTOMETRIC DETECTION OF CONFORMATIONS OF pRB IN SINGLE CELLS
DE19829473C2 (de) * 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Verfahren zur frühen Diagnose von Carcinomen
US7306926B2 (en) * 1998-07-01 2007-12-11 Mtm Laboratories Ag Method for detecting carcinomas in a solubilized cervical body sample
US6593084B2 (en) 1998-10-13 2003-07-15 Robert E. Bird Carcinogen assay
US6864066B1 (en) * 1999-09-08 2005-03-08 The Regents Of The University Of California Epithelial protein lost in neoplasm (EPLIN)
WO2001035903A2 (en) * 1999-11-16 2001-05-25 Kurnick, James, T. Compositions and methods for regulating tumor-associated antigen expression
EP1234185B1 (de) 1999-11-29 2008-07-09 Beth Israel Deaconess Medical Center Pin1 als stadiumsmarker der aggressivität und/oder der metastasierung abnormale zellwachstum
DE10014685B4 (de) 2000-03-24 2004-07-01 Schubert, Walter, Dr. Verfahren zur Identifizierung von zellspezifischen Zielstrukturen
US20020164668A1 (en) * 2000-04-03 2002-11-07 Durham L. Kathryn Nucleic acid molecules, polypeptides and uses therefor, including diagnosis and treatment of alzheimer's disease
GB0018140D0 (en) * 2000-07-24 2000-09-13 Medical Res Council Screening for abnormalities
AUPQ901700A0 (en) * 2000-07-26 2000-08-17 National Cancer Centre Of Singapore Pte Ltd Molecular markers
WO2002020617A1 (en) 2000-09-01 2002-03-14 International Bioimmune Systems, Inc. The identification and development of specific monoclonal antibodies to squamous cell carcinoma
US6548252B1 (en) * 2000-10-13 2003-04-15 Esa, Inc. Detection of DNA damage
DE10063179A1 (de) * 2000-12-18 2002-06-20 Bayer Ag Verfahren zur spezifischen Detektion von Tumorzellen und ihren Vorstufen in Gebärmutterhalsabstrichen durch simultane Messung von mindestens zwei verschiedenen molekularen Markern
US6500630B2 (en) * 2001-01-12 2002-12-31 Mayo Foundation For Medical Education And Research Marker for inflammatory conditions
EP1369694A1 (de) 2002-04-09 2003-12-10 MTM Laboratories AG Verfahren zur Unterscheidung zwischen Metaplasien und neoplastischen oder präneoplastischen Läsionen
DK1388734T3 (da) 2002-08-01 2004-05-03 Mtm Lab Ag Metode til opløsningsbaseret diagnose
EP1422526A1 (de) 2002-10-28 2004-05-26 MTM Laboratories AG Verfahren zur verbesserten Diagnose von Dysplasien
CA3117744C (en) 2008-09-04 2022-07-19 Ventana Medical Systems, Inc. Method for prediction of the progression risk of tumors

Also Published As

Publication number Publication date
JP2010266460A (ja) 2010-11-25
US7517662B2 (en) 2009-04-14
JP2015180201A (ja) 2015-10-15
MXPA04012648A (es) 2005-03-23
AU2003262554B2 (en) 2009-02-19
WO2004013632A1 (en) 2004-02-12
CN1675550A (zh) 2005-09-28
AU2003262554A1 (en) 2004-02-23
US20150065383A1 (en) 2015-03-05
CA2487048A1 (en) 2004-02-12
US20090181406A1 (en) 2009-07-16
EP1388734B1 (de) 2004-03-03
JP2005534313A (ja) 2005-11-17
DE60200248T2 (de) 2005-01-27
CA2487048C (en) 2010-08-17
JP5997094B2 (ja) 2016-09-28
RU2005101643A (ru) 2005-06-27
CN100570366C (zh) 2009-12-16
DK1388734T3 (da) 2004-05-03
US10697966B2 (en) 2020-06-30
EP1388734A1 (de) 2004-02-11
EP1525476A1 (de) 2005-04-27
ES2215957T3 (es) 2004-10-16
DE60200248D1 (de) 2004-04-22
US20040023288A1 (en) 2004-02-05
JP2013210373A (ja) 2013-10-10
RU2315312C2 (ru) 2008-01-20

Similar Documents

Publication Publication Date Title
ATE261126T1 (de) Verfahren für lösung-basierte diagnose
Bilous et al. Current perspectives on HER2 testing: a review of national testing guidelines
Norris et al. Imaging mass spectrometry: a new tool for pathology in a molecular age
CA2573732A1 (en) Automated system of processing biological specimens and method
RU2004135411A (ru) Цепь сохранности флюидов
EP2770328A3 (de) Verfahren zur Diagnose von Bauchspeicheldrüsenkrebs
US20220389523A1 (en) Image acquisition methods for simultaneously detecting genetic rearrangement and nuclear morphology
WO2007103430A3 (en) Method and system for generating sample plate layout for validation
Park et al. Silver-enhanced in situ hybridization as an alternative to fluorescence in situ hybridization for assaying HER2 amplification in clinical breast cancer
US8969031B2 (en) Automated cell density adjustment method for producing an analysis plate
ATE437365T1 (de) Probentestträger und verfahren zur prüfung von okkultem blut im stuhl
BRPI0901542A2 (pt) dispositivo leitor de microtubo para a análise de amostras de sangue
US7678581B2 (en) Correlating chemical and spatial data within pathology samples
Huang et al. Extent of agreement between the body fluid model of Sysmex XN‐20 and the manual microscopy method
Komori et al. Comparative study of sperm motility analysis system and conventional microscopic semen analysis
CN106706692A (zh) 一种基于代谢组学技术的农药毒性评价方法
Innaro et al. Minimal residual disease assessment of papillary thyroid carcinoma through circulating tumor cell‐based cytology
JP2010117290A (ja) 液体試料成分の分析装置および分析方法
Keyser Artifacts and artefacts: A methodological classification of context-specific regularities
WO2022271865A9 (en) Protein biomarker indicators of neurological injury and/or disease and methods of use thereof
KR101477421B1 (ko) 차량 부품 도막 노화도 평가방법
Kurdi Neuromuscular Pathology Made Easy
DE60041203D1 (de) Verfahren zur verifikation der verwendung eines bestimmten färbemittels für eine zellprobe
US20220106635A1 (en) Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
Gu Developing Spatialomics Platforms to Profile Biomarkers

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties